AbbVie's CEO hinted his company may be less willing to invest in psychiatry after a costly setback, while Lilly explained ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...

Hindenburg Research founder Nate Anderson, a foe of Carl Icahn and the Adani family, cites the stress of his job as he shuts down the firm.

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

The world's largest contract chip maker reported another record quarter as it continued to ride the AI wave while navigating the U.S.-China chip rivalry. The fatal shooting revealed deep resentment of ...

COPENHAGEN - The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

In this episode of "Shelf Portrait," comedian and host Lilly Singh gives Marie Claire a look at her eye-catching, topsy-turvy bookshelves filled with books by several of her favorite South Asian ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

The FDA approved Eli Lilly’s Omvoh in Crohn’s disease, the company announced Wednesday, handing the drug its second ...

Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...